Ascendancy Healthcare, dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, has announced a multi-year collaboration with Quintiles, a provider of biopharmaceutical development and commercial outsourcing services.
Quintiles will provide product assessments and clinical research services including trial planning, productivity optimization and execution of cost-efficient studies for therapeutic compounds Ascendancy in-licenses for development and commercialization in China and other Asian markets.
The agreement will span a full spectrum of clinical development activities necessary for the registration of products for commercialization in China. The collaboration will be overseen by a joint development committee composed of representatives from both organizations. The two-and-a-half year agreement has an option for both organizations to renew for an additional two and a half years.
"This deal illustrates Quintiles' ability to provide customized solutions in China for customers anywhere in the world,” said Ling Zhen, general manager for Quintiles' operations in China. “By combining our expertise in product assessment from Quintiles' team in China and clinical trial services through our local CRO, Kun Tuo, we can fully support Ascendancy across the value chain, from strategy development to clinical execution to product approval and market access."